Previous studies suggested that there was no significant difference in safety and efficacy between basal-bolus insulin therapy (4 times/day) or thrice-daily premixed insulin in patients with type 2 diabetes mellitus (T2DM) (Jia et al., 2015; Bellido et al., 2015). This evidence concerns the gene INS and diabetes mellitus.